Jazz Pharmaceuticals PLC $JAZZ Stock Position Reduced by Ameriprise Financial Inc.

Key Points

• Ameriprise Financial Inc. reduced its stake in Jazz Pharmaceuticals by 8.3%, selling 151,896 shares, and now holds about 2.72% of the company, valued at approximately $208 million.
• Jazz Pharmaceuticals reported a significant earnings miss with a loss of $8.25 per share, compared to analyst expectations of a loss of $5.61, while its revenue for the quarter was $1.05 billion, aligning with forecasts.
• Brokerage firms are adjusting their price targets for Jazz Pharmaceuticals, with recent estimates ranging from $147 to $202, signaling cautious optimism amid a consensus rating of "Moderate Buy."

Ameriprise Financial Inc. lowered its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 8.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,675,762 shares of the specialty pharmaceutical company's stock after selling 151,896 shares during the period. Ameriprise Financial Inc. owned 2.72% of Jazz Pharmaceuticals worth $208,026,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Martingale Asset Management L P boosted its stake in Jazz Pharmaceuticals by 116.8% during the 1st quarter. Martingale Asset Management L P now owns 8,641 shares of the specialty pharmaceutical company's stock worth $1,073,000 after purchasing an additional 4,656 shares during the period. Groupama Asset Managment raised its position in Jazz Pharmaceuticals by 7.6% during the 1st quarter. Groupama Asset Managment now owns 8,718 shares of the specialty pharmaceutical company's stock worth $1,072,000 after buying an additional 619 shares during the last quarter. Fuller & Thaler Asset Management Inc. raised its position in Jazz Pharmaceuticals by 41.7% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company's stock worth $165,245,000 after buying an additional 391,660 shares during the last quarter. Wellington Management Group LLP raised its position in Jazz Pharmaceuticals by 141.5% during the 1st quarter. Wellington Management Group LLP now owns 100,962 shares of the specialty pharmaceutical company's stock worth $12,534,000 after buying an additional 59,159 shares during the last quarter. Finally, Northern Trust Corp raised its position in Jazz Pharmaceuticals by 0.8% during the 1st quarter. Northern Trust Corp now owns 525,163 shares of the specialty pharmaceutical company's stock worth $65,199,000 after buying an additional 3,967 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Up 1.2%

Shares of NASDAQ:JAZZ traded up $1.48 during midday trading on Monday, reaching $124.59. The company had a trading volume of 1,011,665 shares, compared to its average volume of 842,579. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The stock's fifty day moving average price is $113.03 and its 200-day moving average price is $117.13. The stock has a market capitalization of $7.56 billion, a P/E ratio of -18.51, a PEG ratio of 7.76 and a beta of 0.34. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm's quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the firm posted $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Equities research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the sale, the chief executive officer owned 436,973 shares in the company, valued at approximately $47,031,403.99. The trade was a 0.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.30% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Zacks Research upgraded shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Robert W. Baird decreased their price target on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 20th. Royal Bank Of Canada decreased their target price on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $147.00 price target (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Thirteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $181.43.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.